IRVINGTON, N.Y., Oct. 25, 2013 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (Nasdaq:MELA), the medical device company that has developed and is commercializing MelaFind®, the first and only FDA approved optical diagnostic device for melanoma detection used by dermatologists in their fight against melanoma, today announced that the company will be participating in the Washington D.C. Dermatological Society'sFall Clinical Conference taking place October 26, 2013 in Falls Church, Virginia.
The Washington D.C. Dermatological Society'sFall Clinical Conference is a half-day medical meeting that is well attended by approximately 100 dermatologists, as well as physician assistants and nurse practitioners who specialize in dermatology. The Program Director and Moderator of the conference will be Amir A. Bajoghli, MD, Assistant Clinical Professor of Dermatology at Georgetown University and Chief of Dermatology at INOVA Fairfax Hospital.
The conference is a hands-on symposium involving live patient case studies and pathology analysis. This interactive activity provides physicians with practical information regarding rare dermatologic conditions, as well as common problems that manifest themselves in unique ways. Attendees will also evaluate diagnostic testing and imaging in dermatology. Physicians and other health care providers will have the opportunity to consider current standards of care, as well as recommendations for optimizing patient care. The overreaching goal for this conference is to update the practicing dermatologist and generalist in topics that will improve patient care.
"We are pleased to have MELA Sciences attending our conference, and look forward to learning more about the company and working with their digital, spectral imaging system, MelaFind," said Dr. Bajoghli. While we believe MelaFind will be a valuable tool when making biopsy decisions, we are also focused on exploring the value of providing these images to our dermatopathologists as these atypical lesions are being assessed for biopsy. The ability for the first time to image up to 2.5 mm below a lesion should provide additional information, which can then be used in determining a proper course of diagnosis and subsequent treatment."
According to the Skin Cancer Foundation, melanoma is currently the deadliest and fastest growing cancer in the U.S., with one American dying from melanoma every hour. Skin cancer has reached epidemic proportions, even though the cause (ultraviolet rays) and prevention (sun protection) is known. Melanoma is almost 100% curable if caught early, but according to a Harris Interactive Study commissioned by MELA Sciences only 24 percent of American adults have had a skin check by a dermatologist, which can lead to missed cases as well as potentially advanced and fatal stages.
MelaFind® is the first and only FDA-approved optical imaging device for melanoma detection used by dermatologists and was recognized by the Cleveland Clinic as a Top 10 Medical Innovation for 2013. MelaFind® was featured in the Wall Street Journal, and recently received national attention on "The Rachael Ray Show". Consumers can learn more about the device or locate a MelaFind® dermatologist in their area by visiting www.melafind.com.